


CLAIMS:


1. The use of a compound of Formula (I),




Formula (I)

wherein:


- R^1 is selected from: hydrogen, optionally substituted C_{1-6} alkyl, optionally substituted aryl or optionally substituted aryl C_{1-6} alkyl, wherein the optional substituents are selected from C_{1-4} alkyl, nitro, cyano, fluoro and C_{1-4} alkoxy;
- R^2 is an optionally substituted mono or bi-cyclic aromatic ring, wherein the optional substituents are 1, 2 or 3 substituents independently selected from: cyano, $R^e R^f N$ -, C_{1-6} alkyl, C_{1-6} alkoxy, halo, halo C_{1-6} alkyl or halo C_{1-6} alkoxy wherein R^e and R^f are independently selected from hydrogen, C_{1-6} alkyl or aryl;
- R^3 is selected from a group of Formula (IIa) to Formula (IId):




Formula (IIa)



Formula (IIb)




Formula (IIc)




Formula (IId)

- where R^6 and R^{6a} are independently selected from hydrogen, fluoro, optionally substituted C_{1-6} alkyl, C_{1-6} alkoxy, or R^6 and R^{6a} taken together and the carbon atom to which they are attached form a carbocyclic ring of 3-7 atoms or R^6 and R^{6a} taken together and the carbon atom to which they are attached form a carbonyl group;

- 89 -



or when **A** is not a direct bond the group forms a carbocyclic ring of 3-7 carbon atoms or a heterocyclic ring containing one or more heteroatoms;



or the group forms a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;

5 **R**⁷ is selected from: hydrogen or C₁₋₆alkyl;

R⁸ is selected from:

- (i) hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, haloC₁₋₆alkyl, C₁₋₄alkoxyC₁₋₄alkyl, hydroxy, hydroxyC₁₋₆alkyl, cyano, N-C₁₋₄alkylamino, N,N-di-C₁₋₄alkylamino, C₁₋₆alkyl-S(O)_n-, -O-**R**^b, -N**R**^b**R**^c, -C(O)-**R**^b, -C(O)O-**R**^b, -CON**R**^b**R**^c, NH-C(O)-**R**^b or -S(O)_nN**R**^b**R**^c,

where **R**^b and **R**^c are independently selected from hydrogen and C₁₋₆alkyl optionally substituted with hydroxy, amino, N-C₁₋₄alkylamino, N,N-di-C₁₋₄alkylamino, HO-C₂₋₄alkyl-NH- or HO-C₂₋₄alkyl-N(C₁₋₄alkyl)-;

- (ii) nitro when **B** is a group of Formula (IV) and **X** is CH and **p** is 0;


- (iii) carbocyclyl (such as C₃₋₇cycloalkyl or aryl) or arylC₁₋₆alkyl each of which is optionally substituted by **R**¹², or **R**¹³;


- (iv) heterocyclyl or heterocyclylC₁₋₆alkyl each of which is optionally substituted by up to 4 substituents independently selected from **R**¹² or **R**¹³, and where any nitrogen atoms within a heterocyclyl group are, where chemically allowed, optionally in their oxidised (N→O, N-OH) state;

A is selected from:

- (i) a direct bond;
- (ii) optionally substituted C₁₋₅alkylene wherein the optional substituents are independently selected from: hydroxy, hydroxyC₁₋₆alkyl, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, aryl or arylC₁₋₆alkyl;
- (iii) a carbocyclic ring of 3-7 atoms;
- (iv) a carbonyl group or -C(O)-C(**R**^d**R**^d)-, wherein **R**^d is independently selected from hydrogen and C₁₋₂alkyl;


- 90 -

or when R^3 is a group of Formula (IIa) or (IIb), the group  forms a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;

or when R^3 is a group of Formula (IIa), (IIb), (IIc) or (II d), the group  forms a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;

5 **B** is selected from:

- (i) a direct bond;
- (ii) a group of Formula (IV)



Formula (IV)

10 wherein:

X is selected from N or CH,


wherein at position (a) Formula (IV) is attached to the nitrogen atom and the $(CH_2)_p$ group is attached to R^8 ; and

- 15 (iii) a group independently selected from: optionally substituted C_{1-6} alkylene, optionally substituted C_{3-7} cycloalkyl, optionally substituted C_{3-6} alkenylene, optionally substituted C_{3-6} alkynyl, $(C_{1-5}alkyl)_{aa}-S(O_n)-(C_{1-5}alkyl)_{bb-}$, $-(C_{1-5}alkyl)_{aa}-O-(C_{1-5}alkyl)_{bb-}$, $-(C_{1-5}alkyl)_{aa}-C(O)-(C_{1-5}alkyl)_{bb-}$ or $(C_{1-5}alkyl)_{aa}-N(R^{17})-(C_{1-5}alkyl)_{bb-}$, or $-(C_{1-5}alkyl)_{aa}-C(O)NH-(C_{1-5}alkyl)_{bb-}$


where R^{17} is hydrogen or C_{1-4} alkyl, or where R^{17} and the $(C_{1-5}alkyl)_{aa}$ or $(C_{1-5}alkyl)_{bb}$ chain can be joined to form a heterocyclic ring, wherein aa and bb are independently 0 or 1 and the combined length of $(C_{1-5}alkyl)_{aa}$ and $(C_{1-5}alkyl)_{bb}$ is less than or equal to C_5 alkyl and wherein the optional substituents are independently selected from R^{12} , or the group $-B-R^8$ represents a group of Formula (V)

20


- 91 -



Formula (V);



or the group together forms an optionally substituted heterocyclic ring containing 4-7 carbon atoms, wherein the optional substituents are selected from 1 or 2 substituents independently selected from R^{12} and R^{13} ;




or the group forms a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;

R^{11} is selected from: hydrogen, optionally substituted C_{1-6} alkyl, $N(R^{23}R^{24})$ or $NC(O)OR^{25}$, where R^{23} , R^{24} and R^{25} are independently selected from: hydrogen, hydroxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, an optionally substituted carbocyclic ring of 3-7 atoms, optionally substituted heterocyclyl or optionally substituted heterocyclyl C_{1-6} alkyl or R^{23} and R^{24} taken together with the nitrogen atom to which they are attached, can form an optionally substituted ring of 3-10 atoms,

wherein the optional substituents are selected from R^{12} and $\frac{1}{2}K-R^8$ where K and R^8 are as defined herein;

J is a group of the formula: $-(CH_2)_s-L-(CH_2)_s-$ or $-(CH_2)_s-C(O)-(CH_2)_s-L-(CH_2)_s-$ wherein when s is greater than 0, the alkylene group is optionally substituted,



or the group together forms an optionally substituted heterocyclic ring containing 4-7 carbon atoms, wherein the optional substituents are selected from 1 or 2 substituents independently selected from R^{12} and R^{13} ;

K is selected from: a direct bond, $-(CH_2)_{s1}-$, $-(CH_2)_{s1}-O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-C(O)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-S(O_n)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(R^{17a})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-C(O)N(R^{17a})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(R^{17a})C(O)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(R^{17a})C(O)N(R^{17a})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-OC(O)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-C(O)O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(R^{17a})C(O)O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-OC(O)N(R^{17a})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-OS(O_n)-(CH_2)_{s2}-$, or $-(CH_2)_{s1}-S(O_n)-O-(CH_2)_{s2}-$,

- 92 -

$-(CH_2)_{s1}-S(O)_2N(R^{17a})-(CH_2)_{s2}-$ or $-(CH_2)_{s1}-N(R^{17a})S(O)_2-(CH_2)_{s2}-$; wherein the $-(CH_2)_{s1}-$ and $-(CH_2)_{s2}-$ groups are independently optionally substituted by hydroxy or C_{1-4} alkyl and wherein when $s1 > 1$ or $s2 > 1$ then the CH_2 group can optionally be a branched chain;


where R^{17a} is hydrogen or C_{1-4} alkyl;

5 L is selected from optionally substituted aryl or optionally substituted heterocyclyl;

R^4 is selected from hydrogen, C_{1-4} alkyl or halo;

R^5 is selected from a group of Formula III-a; III-b; III-c; III-d; III-e; III-f, III-g, III-h, III-i, or III-j, III-k, III-l, III-m, III-n or III-o

10



wherein:

het represents an optionally substituted 3- to 8-membered heterocyclic ring

15 containing from 1 to 4 heteroatoms independently selected from O, N and S,


- 93 -

wherein the optional substituents are selected from 1-2 groups selected from R^{12} and R^{13} ; and

Q is selected from a direct bond or $-[C(R^{16}R^{16a})]_{1-2}$;

R^{14} and R^{15} are selected from:

- 5 (i) R^{14} selected from hydrogen; optionally substituted C_{1-8} alkyl; optionally substituted aryl; $-R^d-Ar$, where R^d represents C_{1-8} alkylene and Ar represents optionally substituted aryl; and optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; and R^{15} is selected from hydrogen; optionally substituted C_{1-8} alkyl and optionally substituted aryl;
- 10 (ii) wherein the group of Formula (III) represents a group of Formula **III-a**, **III-b**, **III-i**, **III-l** or **III-m**, then the group $NR^{14}(-R^{15})$ represents an optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; or

- 15 (iii) wherein the group of Formula (III) represents structure **III-e**,  represents an optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S;

R^{16} and R^{16a} are independently selected from:

- 20 (i) hydrogen or optionally substituted C_{1-8} alkyl; or
 (ii) R^{16} and R^{16a} together with the carbon to which they are attached form an optionally substituted 3 to 7-membered cycloalkyl ring;

R^{12} is independently selected from: halo, hydroxy, hydroxy C_{1-6} alkyl, oxo, cyano,

- 25 cyano C_{1-6} alkyl, nitro, carboxyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-4} alkyl, C_{1-6} alkoxycarbonyl C_{0-4} alkyl, C_{1-6} alkanoyl C_{0-4} alkyl, C_{1-6} alkanoyloxy C_{0-4} alkyl, C_{2-6} alkenyl, C_{1-3} perfluoroalkyl-, C_{1-3} perfluoroalkoxy, aryl, aryl C_{1-6} alkyl, heterocyclyl, heterocyclyl C_{1-6} alkyl, amino C_{0-4} alkyl, N- C_{1-4} alkylamino C_{0-4} alkyl, N,N-di- C_{1-4} alkylamino C_{0-4} alkyl, carbamoyl, N- C_{1-4} alkylcarbamoyl C_{0-2} alkyl, N,N-di- C_{1-4} alkylaminocarbamoyl C_{0-2} alkyl, aminocarbonyl C_{0-4} alkyl, N- C_{1-6} alkylaminocarbonyl C_{0-4} alkyl, N,N- C_{1-6} alkylaminocarbonyl C_{0-4} alkyl, C_{1-6} alkyl-S(O) $_n$ -amino C_{0-4} alkyl-, aryl-S(O) $_n$ -amino C_{0-2} alkyl-, C_{1-3} perfluoroalkyl-S(O) $_n$ -amino C_{0-2} alkyl-, C_{1-6} alkylamino-S(O) $_n$ - C_{0-2} alkyl-,
- 30

- 94 -

arylamino-S(O)_n-C₀₋₂alkyl-, C₁₋₃perfluoroalkylamino-S(O)_n-C₀₋₂alkyl-,
C₁₋₆alkanoylamino-S(O)_n-C₀₋₂alkyl-; arylcarbonylamino-S(O)_n-C₀₋₂alkyl-,

C₁₋₆alkyl-S(O)_n-C₀₋₂alkyl-, aryl-S(O)_n-C₀₋₂alkyl-, C₁₋₃perfluoroalkyl-,

C₁₋₃perfluoroalkoxyC₀₋₂alkyl; $R^{9'}OC(O)(CH_2)_w$ -, $R^{9''}R^{10''}N(CH_2)_w$ -,

- 5 $R^{9'}R^{10'}NC(O)(CH_2)_w$ -, $R^9R^{10}NC(O)N(R^9)(CH_2)_w$ -, $R^9OC(O)N(R^9)(CH_2)_w$ -, or halo,
wherein *w* is an integer between 0 and 4 and R^9 and R^{10} are independently selected
from hydrogen, C₁₋₄alkyl, C₁₋₄alkylsulphonyl and C₃₋₇carbocyclyl, $R^{9'}$ and $R^{10'}$ are
independently selected from C₁₋₄alkylsulphonyl and C₃₋₇carbocyclyl, and $R^{9''}$ and $R^{10''}$
are C₃₋₇carbocyclyl; wherein an amino group within R^{12} is optionally substituted by
10 C₁₋₄alkyl;

R^{13} is C₁₋₄alkylaminocarbonyl wherein the alkyl group is optionally substituted by 1, 2 or 3
groups selected from R^{12} , or R^{13} is a group -C(O)- R^{18} and R^{18} is selected from an amino acid
derivative or an amide of an amino acid derivative;

M is selected from -CH₂-CH₂- or -CH=CH-;

- 15 *n* is an integer from 0 to 2;

p is an integer from 0 to 4;

s, *s1* and *s2* are independently selected from an integer from 0 to 4, and

s1+s2 is less than or equal to 4;


t is an integer between 0 and 4; and

- 20 or a salt, solvate or pro-drug thereof, in the manufacture of a medicament for


- (a) antagonising gonadotropin releasing hormone activity;
(b) administration to a patient, for reducing the secretion of luteinizing hormone by the
pituitary gland of the patient; and
(c) administration to a patient, for therapeutically treating and/or preventing a sex hormone
25 related condition in the patient.

2. A compound of formula (IA) which is a compound of formula (I) as defined in claim 1,
with the proviso that when




- (i) the group  forms an aromatic carbocyclic ring of 3-7 carbon atoms or an
30 aromatic heterocyclic ring containing one or more heteroatoms, or


- 95 -

- (ii) when R^3 is a group of Formula (IIa) or (IIb), and the group  forms an aromatic heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms; or
- (iii) when R^3 is a group of Formula (IIa), (IIb), (IIc) or (IId), and the group



- forms an aromatic heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms, or



- (iv) when the group  forms an aromatic heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms and A is a direct bond; then R^5 is other than a group III-o.

3. A compound according to claim 2 wherein the group A is selected from (i) a direct bond or (ii) optionally substituted C_{1-5} alkylene wherein the optional substituents are independently selected from: hydroxy, hydroxy C_{1-6} alkyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-4} alkoxy C_{1-4} alkyl, aryl or aryl C_{1-6} alkyl.
4. A compound according to claim 2 or claim 3 which includes a group R^{13} and wherein the group R^{13} is $-C(O)-R^{18}$, and R^{18} is selected from an amino acid derivative or an amide of an amino acid derivative; or a salt, solvate or pro-drug thereof.
5. A compound according to any one of claims 2 to 4 wherein R^1 is selected from hydrogen, optionally substituted C_{1-6} alkyl or optionally substituted aryl C_{1-6} alkyl, wherein the optional substituents are selected from: fluoro and C_{1-4} alkoxy.

- 96 -


6. A compound according to any one of claims 2 to 5 wherein R^2 is phenyl, optionally substituted by one or more groups selected from methyl, ethyl, methoxy, ethoxy, *tert*-butoxy, F or Cl.

5 7. A compound according to any one of claims 2 to 6 wherein R^3 is selected from a group of formula (IIc) or formula (IId).

8. A compound according to any one of claims 2 to 7 wherein R^4 is selected from hydrogen, methyl, ethyl, chloro or bromo.

10


9. A compound according to any one of claims 2 to 8 wherein R^5 is selected from a group of Formula III-a, III-g, III-h, III-i, III-j, III-k, III-l: or III-o



wherein R^{16} , R^{16a} , R^{14} and R^{15} are as defined in claim 1.

15

10. A compound according to claim 9 wherein R^5 is a group of formula




11. A compound according to any one of claims 2 to 10 wherein M is $-CH_2-CH_2-$.

20

- 97 -


12. A compound of Formula (Ia)




Formula (Ia)

wherein:

5 R^3 is selected from a group of Formula (IIa) or Formula (IIb):




Formula (IIa)



Formula (IIb)

R^7 is selected from: hydrogen or C_{1-6} alkyl;

B is a group of Formula (IV)




Formula (IV)

and p , **A**, **X**, **M**, R^1 , R^2 , R^4 , R^5 , R^6 , R^{6a} , R^8 , and R^{11} are as defined above for a compound of Formula (I)

or a salt, solvate or pro-drug thereof.

15

13. A compound of Formula (Ic)




Formula (Ic)


wherein:

20 R^3 is selected from a group of Formula (IIc) or Formula (IId):

- 98 -




Formula (IIc)



Formula (IIId)

wherein



the group together forms an optionally substituted heterocyclic ring

5 containing 4-7 carbons atoms, wherein the optional substituents are selected from 1 or 2 substituents independently selected from R¹² and R¹³;

and A, M, J, R¹, R², R⁴, R⁵, R⁶, R^{6a}, R⁸, and R¹² and R¹³ are as defined in claim 1, or a salt, solvate or pro-drug thereof.

10 14. A compound selected from:

3-[3,3-Dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(morpholin-4-ylcarbonyl)piperidin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1H-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)but-2-en-1-yl]-4-

15 [1s-methyl-2-(n'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido) ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-Dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-

[1S-methyl-2-(N'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido) ethyl]-5-(3,5-dimethylphenyl)-1H-pyrrole;

3-[3,3-Dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(pyrrolidin-1-

20 ylcarbonyl)piperazin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1H-pyrrole;

2-chloro-3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(pyrrolidin-1-ylcarbonyl)piperazin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(4-hydroxypiperidin-1-ylcarbonyl)piperidin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

25 3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-

(1,1-dioxo-isothiazolidin-2-ylcarbonyl)-4-methoxy-piperidin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

- 99 -

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{1-benzyl-pyrroldin-3-ylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-(2-{4-n-isopropylureidophenyl}ethylamino)ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;


5 3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{4-(pyrid-4-yl)piperidin-1-ylcarbonylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{3-(pyrid-4-yl)pyrrolidin-1-ylcarbonylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole; and


10 3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{4-phenylpiperidin-1-ylcarbonylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole.

15. A process for preparing a compound of formula (I) as defined in claim 1, or a compound according to any one of claims 2 to 14, said process comprising a step selected from (a) to (h):

15 (a) reaction of a compound of formula XXXII with a compound of formula $H-R^{3'}$,




XXXII



wherein X^1 is selected from:

; L^1 is a displaceable group; and


group; and




$H-R^{3'}$ is selected from:

20 (b) reaction of a compound of formula XXXIII with a compound of formula $L^2-R^{3''}$,

- 98 -




Formula (IIc)



Formula (IIId)

wherein



the group together forms an optionally substituted heterocyclic ring

containing 4-7 carbons atoms, wherein the optional substituents are selected from 1 or 2 substituents independently selected from R¹² and R¹³;

and A, M, J, R¹, R², R⁴, R⁵, R⁶, R^{6a}, R⁸, and R¹² and R¹³ are as defined in claim 1,

or a salt, solvate or pro-drug thereof.

14. A compound selected from:

3-[3,3-Dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(morpholin-4-ylcarbonyl)piperidin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1H-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)but-2-en-1-yl]-4-

[1S-methyl-2-(n'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido) ethyl]-5-

(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-Dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-

[1S-methyl-2-(N'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido) ethyl]-5-(3,5-dimethylphenyl)-1H-pyrrole;

3-[3,3-Dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(pyrrolidin-1-

ylcarbonyl)piperazin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1H-pyrrole;

2-chloro-3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(pyrrolidin-1-ylcarbonyl)piperazin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(4-hydroxypiperidin-1-ylcarbonyl)piperidin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-


(1,1-dioxo-isothiazolidin-2-ylcarbonyl)-4-methoxy-piperidin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

- 99 -


- 3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{1-benzyl-pyrrodin-3-ylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;
 3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-(2-{4-n-isopropylureidophenyl}ethylamino)ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;
 5 3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{4-(pyrid-4-yl)piperidin-1-ylcarbonylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;
 3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{3-(pyrid-4-yl)pyrrolidin-1-ylcarbonylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole; and
 10 3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{4-phenylpiperidin-1-ylcarbonylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole.

15. A process for preparing a compound of formula (I) as defined in claim 1, or a compound according to any one of claims 2 to 14, said process comprising a step selected from (a) to (h):

- 15 (a) reaction of a compound of formula XXXII with a compound of formula $H-R^{3'}$,




XXXII




wherein X^1 is selected from:
 group; and

; L^1 is a displaceable




$H-R^{3'}$ is selected from:

- 20 (b) reaction of a compound of formula XXXIII with a compound of formula $L^2-R^{3''}$,



XXXIII




wherein X^2 is selected from:

; L^2 is a displaceable

group and R^{7a} is selected from the definition of R^7 or R^{22} above, and


$L^2-R^{3''}$ is selected from: L^2-B-R^8 , $L^2-J-K-R^8$ and L^2-R^{21}

- 5 (c) for compounds of Formula (I) or (IA) wherein R^7 is other than part of a heterocyclic ring or hydrogen, reaction of a compound of Formula (I) or (IA) wherein R^3 is a group of Formula (IIa), (IIb), (IIc) or (IId) and R^7 is hydrogen with a group of formula L^3-R^{7a} , wherein R^{7a} is as defined above for R^7 with the exclusion of hydrogen and L^3 is a displaceable group;
- 10 (d) for compounds of Formula (I) or (IA) wherein R^4 is hydrogen, reduction of a thienopyrrole of Formula XXXVIII



XXXVII


- (e) for compounds of Formula (I) wherein R^3 is a group of Formula (IIc) or (IId) and




the group together forms an optionally substituted nitrogen-containing heterocyclic ring containing 4-7 carbon atoms, reaction of a compound of Formula XXXIVa or XXXIVb, with a compound of Formula L^6-K-R^8 , wherein L^6 is a displaceable group

15

- 101 -




XXXIVa




XXXIVb

- (f) for compounds of Formula (I) wherein R^3 is a group of Formula (IIc) or (IId), reaction of a compound of Formula XXXVa or XXXVb, with a compound of Formula $L^7-K''-R^8$, wherein L^7 is a displaceable group, and wherein the groups K' and K'' comprise groups which when reacted together form K ,



XXXVa




XXXVb

- (g) reaction of a compound of Formula XXXVI with an electrophilic compound of the formula L^8-R^3 , wherein L^8 is a displaceable group



XXXVI

- 10 (h) reaction of a compound of Formula XXXIX with an appropriate electrophilic reagent to give a compounds of Formula (I)



XXXIX

and thereafter if necessary, carrying out one or more of the following steps:

- 15 i) converting a compound of the Formula (I) into another compound of the Formula (I);
ii) removing any protecting groups;

- 102 -

iii) forming a salt, pro-drug or solvate.

16. A pharmaceutical formulation comprising a compound according to any one of claims
2 to 14, or salt, pro-drug or solvate thereof, and a pharmaceutically acceptable diluent or
5 carrier.

17. A method of antagonising gonadotropin releasing hormone activity in a patient,
comprising administering a compound of formula (I) or (IA), or salt, pro-drug or solvate
thereof, to a patient.

10

18. A compound according to any one of claims 2 to 14 for use as a medicament.